ENO2 and leukemia: In order to ensure that the observed phenomenon is not caused by innate anticancer activity PC or PC-NSE, their impact on the same doses, used for delivery of Dx (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg and 1 mg/kg) to mice were addressed in separate studies on NK/Ly lymphoma and L1210 leukemia.